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Diabetes is a disease of elevated blood glucose related
to inadequate insulin production and⁄or utilisation.
The progressive b-cell failure associated with type 2
diabetes contributes to the inevitable deterioration of
glucose control over time and the need for increas-
ingly aggressive treatment regimens (1,2). Diabetes
represents a growing worldwide epidemic and is a
major global health and economic concern. Evidence
has indicated that both the prevalence and incidence
of diabetes are on the rise, with both increasing by
approximately 5% annually in the US over the past
15 years (3,4).
The availability of multiple pharmacological agents
has extended the duration of time during which
patients with type 2 diabetes can maintain glycaemic
control using OADs alone (5). The likelihood of
success with any OAD management strategy, however,
is dependent on factors such as patient lifestyle
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Objective: To evaluate oral antidiabetes drug (OAD) use, haemoglobin A1c (HbA1c)
testing and glycaemic control in type 2 diabetes patients. Study design: Retrospec-
tive analysis based on claims data from the Integrated Healthcare Information Ser-
vices (IHCIS) National Managed Care Benchmark Database. Methods: OAD use and
HbA1c testing were analysed for patients with ‡ 2 claims indicating diagnosis of type
2 diabetes and ‡ 1 90-day OAD treatment period between 1 January, 2000 and 30
June, 2006. Likelihood of HbA1c testing was examined using multivariable logistic
regression analyses, adjusting for OAD regimen and patients’ sociodemographical
characteristics. Results: Patients were classiﬁed based on initial OAD regimen:
metformin (MET) (n = 22,203; 41.3%), sulphonylurea (SFU) (n = 18,439; 34.3%),
thiazolidinedione (TZD) (n = 7663; 14.3%), SFU + MET (n = 5467; 10.2%) and
TZD + MET (n = 2355; 4.2%). A total of 51.5% of patients had HbA1c testing dur-
ing 90 days preceding OAD initiation through regimen completion. Approximately,
65% of MET and 58% of SFU patients had no titration of initial regimen. Patients
demonstrating inadequate glucose control decreased from 68.5% at baseline to
46.9% within 90 days of regimen initiation. Multivariable logistic regression indi-
cated several negative predictors of HbA1c testing, including SFU use, age 65+ years,
moderate insurance copayment and preindex inpatient utilisation. Multivariable logis-
tic regression of variables associated with reduced likelihood of up-titration included
TZD, SFU + MET, or TZD + MET treatment, age 18–34 years, Medicare insurance
and any preindex healthcare utilisation. Conclusions: Patients are not being transi-
tioned to additional OADs in a stepwise fashion and⁄or are receiving inadequate
titration on current OAD regimens. The low rate of HbA1c testing and rates of control
are contributing factors.
What’s known
• The availability of multiple pharmacological
agents has extended the duration of time during
which patients with type 2 diabetes can maintain
glycaemic control using oral antidiabetes drugs
(OADs) alone.
• Research has shown, however, that even in well-
managed healthcare organisations that follow
standardised treatment protocols, patients with
inadequate glycaemic control frequently
experience suboptimal management of OAD
treatment regimens, in particular, and delays in
therapeutic transitions or up-titrations.
Furthermore, evidence has indicated that HbA1c
testing is substantially underutilised, despite the
current American Diabetes Association (ADA)
recommendation for biannual HbA1c
measurements, with more frequent testing (every
3 months) when glucose levels are not well
controlled.
What’s new
This large claims analysis examined OAD regimen
usage patterns, as well as haemoglobin A1c (HbA1c)
testing frequency and control, among a large
population of patients with type 2 diabetes.
• Only 52% of patients received an HbA1c test at
any time during their OAD regimen. Many
(68.5%) demonstrated inadequate glucose
control in the 90 days following OAD initiation.
Only a minority (32.5%) received any OAD
titrations during treatment.
• The results of this study verify that inadequate
HbA1c testing and control, as well as a lack of
timely, stepwise OAD transitions and ⁄or titrations
are common in the US.
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guidelines and stepped prescribing patterns (5–10).
With recent evidence indicating the potential beneﬁt
of more aggressive, stepwise therapy in type 2 diabetes,
a number of algorithms have been published to facili-
tate timely treatment transitions in response to persis-
tently elevated glucose levels (5,11,12). Research has
shown, however, that even in well-managed healthcare
organisations that follow standardised treatment pro-
tocols, patients with inadequate glycaemic control fre-
quently experience suboptimal management of OAD
treatment regimens, in particular, delays in therapeutic
transitions or up-titrations (7,13,14).
HbA1c is currently the standard serum marker
applied to assess overall glycaemic control in patients
with diabetes. Although national guidelines agree that
targeting an HbA1c level of < 7% or even lower is
desirable for the majority of patients (15,16), HbA1c
control remains elusive for most patients. Results
from one national survey conducted in 2004 revealed
that 73% of individuals with type 2 diabetes had
HbA1c levels that exceeded target (17). Furthermore,
evidence indicated that HbA1c testing is substantially
underutilised, despite the current ADA recommenda-
tion for biannual HbA1c measurements with more
frequent testing (every 3 months) when glucose levels
are not well controlled (16). The most recent data
available from the US Centers for Disease Control’s
Behavioral Risk Factor Surveillance System (BRFSS)
survey indicated that in 2005, only 64.3% of patients
with diabetes self-reported at least 2 HbA1c tests in
the preceding year (18). A registry audit and a study
of a large managed care population conﬁrmed these
ﬁndings, indicating that when lacking any interven-
tion to encourage testing, only approximately 50%
of patients received at least one HbA1c test over
6-month and 1-year periods (19,20).
Thus, existing evidence points to inadequacies in
both the OAD management and HbA1c monitoring
strategies that are currently applied in clinical practice.
It is likely that both of these factors contribute to
suboptimal glycaemic control in patients with type 2
diabetes. The following claims analysis study was
designed to validate these hypotheses through an
examination of usage patterns for speciﬁc OAD
regimens, as well as HbA1c test utilisation and
outcomes, among a large population of patients with
type 2 diabetes.
Research design and methods
Study population
The population for this retrospective analysis was
derived from health insurance claims data and enrol-
ment records for approximately 40 US health plans
using information obtained from the Integrated
Healthcare Information Services (IHCIS) National
Managed Care Benchmark Database. Initial database
screening led to the identiﬁcation of 916,211 individ-
uals with ‡ 2 claims for diabetes mellitus (ICD-
9-CM code 250.xx) during the study period (1 Janu-
ary, 2000, through 30 June, 2006). Members of this
group were eligible for study inclusion if they had:
(i) a diagnosis of type 2 diabetes (ICD-9-CM code
250.x0 or 250.x2 in any listed diagnosis ﬁeld) on ‡ 2
claims during the study period; (ii) had undergone
at least one continuous 90-day period of prescribed
OAD therapy; (iii) were aged ‡ 18 years at the earli-
est OAD ﬁll date; and (iv) exhibited an absence of
documented OAD pharmacy claims in the 180-day
period preceding ﬁrst OAD treatment during the
study period. Individuals with no OAD use during
the study period, non-continuous enrolment in an
included health plan during the OAD treatment per-
iod, or a diagnosis of type 1 diabetes (ICD-9-CM
code 250.x1 or 250.x3) or gestational diabetes (ICD-
9-CM code 648.8) on ‡ 1 claim(s) during the study
period were excluded from analysis.
Oral antidiabetes drug treatment regimens
OAD utilisation histories for the study population
were derived from IHCIS pharmacy claims data. An
OAD regimen was deﬁned as a single prescription
for OAD monotherapy or single-pill combination
therapy, or prescriptions for ‡ 2 OADs combined as
dual therapy, in which sufﬁcient medication was
provided for a treatment period of ‡ 90 days. Dual-
therapy prescriptions were required to be ﬁlled
within 25 days of one another, to ensure that there
was overlapping supply of the two medications. The
start date for a dual-therapy regimen was considered
to be the date on which the second OAD prescrip-
tion was initially ﬁlled. New OAD prescriptions were
distinguished from reﬁlls by a ‡ 180-day clean per-
iod, during which time a patient had no prescrip-
tions ﬁlled for any OAD, but remained continuously
enrolled in an included health plan.
For each patient, the OAD regimen with the earli-
est start date was referred to as their index regimen.
The preindex period was deﬁned as the 180-day per-
iod preceding the start date of an index regimen.
The observation period extended from the start of
the preindex period through disenrolment or study
termination. An OAD regimen was considered ongo-
ing as long as there was no gap in treatment cover-
age (based on daily medication requirements) of
> 120 days for any OADs in the regimen, and provi-
ded that at least one prescription reﬁll was available
for all OADs in the regimen. The end of a regimen
occurred when ‡ 1 OAD(s) were added to and⁄or
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was deﬁned as a gap in treatment coverage of
> 120 days for ‡ 1 OAD(s) in an otherwise ongoing
regimen. Resumption of a treatment regimen follow-
ing a gap of > 120 days was considered equivalent to
the initiation of a new regimen. Censoring of a treat-
ment regimen referred to regimen truncation because
of patient disenrolment from an included health plan
or study termination.
OADs were classiﬁed into six groups: sulphonylu-
reas (SFU), non-sulphonylurea insulin secretagogues
(NIS), metformin (MET), thiazolidinediones (TZD),
alpha-glucosidase inhibitors and other. Appendix S1
provides a list of medications associated with each of
these OAD classes.
OAD titrations and treatment gaps
Data on OAD up-titrations and down-titrations were
captured for analysis. Information included: (i) the
total numbers of each type of titration during each
OAD regimen; (ii) determination of whether HbA1c
testing was performed during the 90-day period pre-
ceding and⁄or the 90-day period following each titra-
tion; and (iii) characterisation of patients’
pretitration and posttitration glucose control levels
based on HbA1c test results. Gaps in OAD treatment
of > 3 days and ‡ 30 days were also noted. Cross-
tabulation analysis was performed to determine the
association between OAD regimen type and titration
patterns and between OAD regimen type and treat-
ment gaps.
HbA1c testing
HbA1c testing patterns and results were captured for
analysis. Information included: (i) the number of
patients undergoing HbA1c testing; (ii) the number of
HbA1c tests performed during each OAD regimen;
(iii) assessment (yes⁄no) of whether HbA1c testing
was performed during the 90-day period preceding
and⁄or the 90-day period following the start date of
each regimen and each OAD up-titration and
down-titration; (iv) assessment (yes⁄no) of whether
HbA1c testing was performed during the 90-day
\period prior to the end date of each regimen; and
(v) an evaluation of HbA1c levels obtained prior to
and throughout the course of each OAD regimen.
Cross-tabulation analysis was performed to determine
the association between OAD regimen type and
HbA1c test results.
Glucose control
Glucose control was assessed based on the results of
HbA1c testing. HbA1c results were categorised based
on currently accepted ADA and Healthcare Effective-
ness Data and Information Set (HEDIS) classiﬁcations
of blood glucose levels as normal (< 6%, used for
sensitivity analyses only), controlled (< 7.0%), subop-
timally (7.0% to 9.5%) or poorly controlled (‡ 9.5%)
(16,21). Note that, at the time of this analysis,
the IHCIS database contained data on laboratory
values for only approximately 2% of all patients. (In
contrast, laboratory claims data were available for
all patients.) The level of glucose control was exam-
ined on the subset of patients for whom laboratory
value data were available [MET, n = 2946 (13.3%);
SFU, n = 2785 (15.1%); TZD, n = 1253 (16.4);
SFU+MET, n = 754, (13.8%); TZD + MET, n = 321
(13.6%)].
Statistical analysis
In addition to the cross-tabulation analyses previ-
ously described, multivariable logistic regression
analyses were performed to model which characteris-
tics were predictive of patients receiving any HbA1c
testing (binary variable: yes⁄no). Separate logistic
regression analyses modelled the factors associated
with greater likelihood of up-titration of the index
OAD regimen. Variables included were OAD treat-
ment, patient age, gender, US region, insurance type,
amount of copayment, insulin use (yes⁄no), inpa-
tient, outpatient, laboratory or other services and
time to ﬁrst OAD after diabetes diagnosis. Analyses
were performed using SAS Institute Inc. software
(SAS ver. 9.1.3, Cary, NC, USA).
Results
Index OAD regimen groups
A total of 420,329 patients satisﬁed the screening
criteria. Although treatment data were collected for
all prescribed OADs, only the most frequently
occurring index OAD regimens in the screened
population were selected for analysis. After exclud-
ing combination regimens consisting of medications
from three or more OAD classes, the distribution
of patients for each of the selected index regimens
was: MET, n = 22,203 (39.6%); SFU, n = 18,441
(32.9%); TZD, n = 7663 (13.7%); SFU + MET,
n = 5467 (9.7%) and TZD + MET, n = 2356
(4.2%).
Sociodemographical and healthcare proﬁles
Analysis of the resulting patient population included
an examination of sociodemographical characteris-
tics, healthcare utilisation, health insurance and treat-
ment histories by index OAD regimen. There were
few differences between index regimen groups with
regard to gender, age, geographical region, health
insurance type and healthcare expenditures during
the preindex year (Table 1).
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HbA1c tests were administered at least once to approx-
imately 51.5% of patients, and fasting plasma glucose
(FPG) testing was administered to 43% of patients
(Table 2). Although most patients began OAD therapy
at approximately the same time as their type 2 diabetes
diagnosis, approximately 18% of patients initiated
OAD treatment more than 1 year following diagnosis.
Index OAD regimen duration, dosing
and treatment gaps
For each index OAD regimen, patients’ treatment
duration, dosing patterns and treatment gaps were
evaluated.
The average index treatment duration was approx-
imately 1 year for all treatment groups except the
SFU + MET and TZD + MET groups, for which the
average treatment length was 295 and 220 days
respectively (Table 3). For all monotherapy index
regimens, index regimens were titrated for 32.5% of
patients at some point during therapy; 14.2% of
patients receiving TZD therapy experienced a regi-
men titration. Patients taking SFU monotherapy
were most likely to experience any up-titration
(33.3%) or down-titration (21.2%), while patients
receiving TZD or TZD + MET were the least likely
to experience any up-titration (10.8% and 14.9%
respectively) or down-titration (6.1% and 6.5%
















Female (%) 46.9 44.6 44.9 45.6 44.3 45.6
Average age (years) (SD) 56.8 (12.1) 57.3 (12.2) 56.6 (11.9) 56.0 (12.0) 57.0 (12.3) 56.9 (12.1)
Age group (years) (%)
18–34 3.8 3.5 3.6 4.15 4.2 3.7
35–44 11.2 11.1 12.1 12.5 10.7 11.4
45–54 25.9 25.3 25.7 27.4 25.1 25.8
55–64 34.3 32.8 34.2 33 34.3 33.4
65+ 24.9 27.3 24.5 23.0 25.9 25.5
US region (%)
Northeast 62.6 65.2 62.3 57.6 56.2 62.7
Midwest 13.2 11.2 12.6 13.7 14.8 12.6
South 16.3 15.6 16.6 19.6 19.7 16.6
West 7.6 6.9 7.8 8.6 9.3 7.6
Other 0.4 1.1 0.7 0.5 0.1 0.6
Health insurance type (%)
PPO 42.6 40.1 44.7 44.9 45.2 42.4
HMO 29.8 28.7 28.4 29.3 25.9 29.0
IND 10.1 8.2 8.7 8.9 12.9 9.3
POS 8.1 8.4 7.7 8.0 9.3 8.2
Medicare 7.2 12.3 8.2 5.8 3.7 8.7
Medicaid 0.7 1.1 1.0 1.3 1.0 0.9
Other 0.1 0.1 0.1 0.1 0.04 0.1
Copayment at time of index Rx (%)
$0 8.2 7.9 7.3 6.7 8.5 7.8
$1–5 15.6 25.5 4.6 8.7 4.2 16.2
$6–10 43.1 33.1 16.4 26.8 17.5 33.5
$11–15 13.7 12.3 13.3 15.7 11.9 13.3
$16–20 12.5 12.0 23.3 21.6 23.4 15.1
$21–35 5.7 7.1 16.4 12.6 18.1 8.9
$35+ 1.4 2.2 18.8 7.9 16.4 5.3
Total HC expenditures in preindex year $1,771.15 $2,359.80 $1,864.22 $1,325.18 $1,572.84 $1,934.00
Any HC utilisation in preindex period 59.6 55.7 38.8 57.4 11.5 53.2
HC, healthcare; HMO, health maintenance organisation; IND, independent; MET, metformin; OAD, oral antidiabetes drug; OTH, other;
POS, point of service; PPO, preferred provider organisation; SD, standard deviation; SFU, sulphonylurea; TZD, thiazolidinedione.
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each index group experienced no index regimen
treatment gaps lasting ‡ 30 days.
HbA1c test utilisation and glycaemic control
Using claims data, an analysis of HbA1c test utilisa-
tion was performed for each index group, including
an evaluation of the number of tests performed, the
timing of tests relative to the index regimen period
and HbA1c levels both at baseline and during the
index regimen (Table 4).
The number and timing of HbA1c tests performed
throughout the index OAD regimen period were
similar across index groups. Approximately, 37% of
TZD patients were administered an HbA1c test at
any time from 90 days prior to OAD initiation
through the end of the regimen, compared with 45%
of MET patients and 38% of SFU patients. HbA1c
tests were administered during the 90 days preceding
the start of the index regimen for 4.7% of all
patients, and 21.7% were tested during the 90 days
following the start of a regimen.
In the small subset of patients for whom laboratory
data were available, the percentage of patients dem-
onstrating suboptimal or poor glucose control on
HbA1c testing decreased from 68.5% at baseline (days




















Index regimen HbA1c testing
(Y⁄N, based on claims data)
54.6 48.3 49.7 51.8 53.9 51.5
Index regimen FPG testing
(Y⁄N, based on claims data)
44.6 43.6 40.9 39 39 43
Time (days) from diagnosis until ﬁrst OAD therapy (%)
0 40.8 49.4 42.4 55.9 43.2 45.4
1–91 19.8 22.1 24 25.7 31.2 22
92–182 5.8 6.1 7.4 3.8 6.1 5.9
183–273 5 4.8 5 3 2.9 4.6
274–364 4.9 3.6 3.9 2.5 3.1 4.2
365+ 23.7 14.2 17.3 9.1 13.6 17.8
FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; MET, metformin; OAD, oral antidiabetes drug; SFU, sulphonylurea;
TZD, thiazolidinedione.















Average index regimen duration (days) 355.3 373.9 333.8 295.3 220.3 346.9
% started on MED 2.3 3.2 7.4 45.5 35.1 7.4
Any regimen titration 34.50% 41.50% 14.20% 26.30% 17.30% 32.50%
Up-titrations
% with 1+ 30.7 33.3 10.8 22.3 14.9 27.3
Average time to ﬁrst (days) 41 54.6 64 41.3 49.6 49
Down-titrations
% with 1+ 11.4 21.2 6.1 11.2 6.5 13.7
Average time to ﬁrst (days) 54.6 65.5 85 52.7 55.1 62.2
Treatment gap(s) > 3 days (% with) 67.4 65.6 62 51.5 46.6 63.6
Treatment gap(s) ‡ 30 days (% with) 32.2 32.4 27.3 26.3 20.8 30.5
MED, maximum effective dose; MET, metformin; OAD, oral antidiabetes drug; SFU, sulphonylurea; TZD, thiazolidinedione.
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who received HbA1c testing ‡ 90 days after the start
of the index regimen. At baseline, the average HbA1c
level for all groups was suboptimal (ranging from
7.7% among MET patients to 8.9% among SFU +
MET patients). Mean HbA1c at ﬁrst test ‡ 90 days
after the start of the index regimen showed the great-
est reduction from mean baseline HbA1c in the
SFU + MET ()1.5) and TZD + MET ()1.4) groups,
whereas the smallest reduction was observed among
MET patients ()0.7); reductions in the SFU and
TZD patients were )1.3 and )1.1 respectively. The
TZD + MET cohort had the largest shift in patients
moving from uncontrolled to controlled between the
baseline HbA1c test and the ﬁrst test ‡ 90 days after
initiating treatment.
Regression analysis
The results of the logistic regression, indicating vari-
ables predictive of patients receiving any HbA1c test
are presented in Appendix S2. Several key predictors
of reduced likelihood of HbA1c testing were identi-
ﬁed including SFU, TZD or TZD + MET treatment
(vs. MET monotherapy), older age (65+ years), hav-
ing Medicare as insurance and having a moderate
insurance copayment ($11–20). Regional variances in
HbA1c testing likelihood were also identiﬁed, with
the West region having the highest likelihood of test-
ing. Amount of copayment was associated with likeli-
hood of receiving an HbA1c test, with patients with
no copayment ($0) more likely to receive a test
[odds ratio (OR), 2.45; 95% conﬁdence interval (CI),
2.21–2.72] and those with higher copayments less
likely, compared with patients with a $6–10 copay-
ment. Any healthcare utilisation in the preindex per-
iod also increased the likelihood of testing (OR, 1.20;
95% CI, 1.15–1.24).
The results of the logistic regression, indicating vari-
ables associated with patients receiving an up-titration
during index regimen are presented in Appendix S3.
Factors associated with reduced likelihood of up-titra-
tion included TZD, SFU + MET, or TZD + MET
treatment (compared with MET), younger age
(18–34 years), Medicare as insurance and any preindex
healthcare utilisation. The amount of copayment was
also associated with likelihood of up-titration, with
patientswithcopayment of$6–10more likelytoreceive
an up-titration than patients in any other copayment
categories. Up-titration of initial OAD regimen was
more likelyfor patients on SFU (vs.MET).
Discussion
This study validated prior research that indicated
that both inadequate HbA1c testing and control, as
well as a lack of timely OAD transitions and⁄or titra-
tions are common in the US and appear to contrib-
ute substantially to inadequate blood glucose levels
in patients with type 2 diabetes (7,13,14). These data
also indicated substantial deviations in HbA1c testing
frequency compared with ADA and American Col-
lege of Endocrinology⁄American Academy of Clinical















Index regimen HbA1c testing (based on claims data) (%)
Any test from 90 days prior
to end of regimen
45.5 38.1 36.6 43.5 37.1 40.1
Within 90 days prestart 6.4 3.5 10.5 2.5 4.1 4.7
Within 90 days after start 24.1 19.5 18.9 22.6 24.1 21.7
Mean no. of tests 2.8 2.5 2.6 2.5 2.4 2.6
(n = 1960) (n = 1594) (n = 849) (n = 393) (n = 252) (n = 5048)
Overall HbA1c results (subsample with laboratory values) (%)
Mean baseline HbA1c 7.7 8.6 8 8.9 8.3 8.2
Mean HbA1c at 1st test ‡
90 days after start
7 7.3 6.9 7.4 6.9 7.2
Baseline (days 0–89) %
not controlled
59.8 78.1 65.4 79.6 67.5 68.5
During regimen (day ‡ 90) %
not controlled
41.8 49.3 41.8 52.4 36.2 46.9
HbA1c, haemoglobin A1c; MET, metformin; OAD, oral antidiabetes drug; SFU, sulphonylurea; TZD, thiazolidinedione.
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tions in place during the majority of the study per-
iod. In 2002, ADA and AACE implemented their
ﬁrst speciﬁc HbA1c testing recommendations, calling
for a minimum of quarterly and biannual testing
respectively (22,23).
This study provides new insight regarding the tim-
ing of testing in clinical practice. Perhaps most sur-
prising is an apparent deﬁcit in FPG or HbA1c
assessment. For example, among patients with any
HbA1c testing, only 0.3% to 1.2% was tested in the
90 days before the start of their index regimen. This
may indicate that pharmacological therapy was initi-
ated without glucose control assessment and⁄or that
other measurements (such as FPG) were used.
Patients were most likely to receive HbA1c testing
within 90 days of starting their OAD regimen (22%);
this is consistent, although not actually adherent,
with then-current ADA recommendations that HbA1c
testing be repeated within 2–3 months of initiation
to assess treatment efﬁcacy (23).
Despite observable improvement in HbA1c control
among patients receiving any index OAD regimen,
almost half failed to attain target glucose (HbA1c
< 7.0%). Prior to OAD initiation, only approxi-
mately 32% of patients were at target; this propor-
tion increased to 53.1% among patients who were
tested at any time during OAD treatment. It should
be noted that because laboratory values were only
available for a modest subsample of the initial
cohort, these results may not represent patterns of
care for the entire cohort and should be interpreted
with caution. However, these results correspond with
a 2004 report evaluating US National Health and
Nutrition Examination Survey (NHANES) outcomes
(1988–1994 and 1999–2000), which found that only
37% of individuals with type 2 diabetes had HbA1c
levels < 7% (17). Likewise, two recent, large claims
and managed care database studies evaluating new
medication use in patients with type 2 diabetes
corroborate that baseline population HbA1c rates are
typically elevated prior to treatment and do not
improve subsequently to the extent that the majority
of patients reach goal (6,24).
The multiple logistic regression model applied to
analyse the discrete variable (yes⁄no, any HbA1c test-
ing) indicated only a moderate estimation of the
observed variance; however, some novel information
was identiﬁed regarding the characteristics of patients
who do and do not receive HbA1c testing. SFU drug
use, older age (65+ years) and the use of inpatient
hospital services and other services during the prein-
dex period were predictive of less testing. Patients
from the mid-Atlantic region (comprising the US
states of NY, NJ and PA) represented a substantive
proportion of the study sample (26.8%) and exhib-
ited a > 50% decreased likelihood of receiving HbA1c
testing compared with the reference group (New
England region, US), as well as with other US
regions or the US as a whole. Variables associated
with receiving HbA1c testing include $0 copayment
and having laboratory services performed during the
preindex period, the latter of which is the single
strongest predictor of testing.
The results of the logistic regression of likelihood of
an up-titration during index regimen indicated that
index regimens of TZD, SFU + MET, or TZD + MET
treatment were less likely to be up-titrated, and those
on SFU were more likely to be up-titrated. In addition,
younger patients and those with Medicare were less
likely to be titrated. Interestingly, the amount of
copayment was also associated with likelihood of
up-titration, but no clear trend was visible, as patients
with copayments less than and more than $6–10 were
less likely to receive an up-titration.
In addition to assess HbA1c levels and testing fre-
quency, this study was designed to evaluate OAD
transition and titration patterns in the context of
glucose control. Since the mid-1990s, the steady
introduction of OADs with distinct mechanisms of
action has made it increasingly feasible to maintain
long-term glycaemic control prior to insulin initia-
tion. The progressive nature of type 2 diabetes path-
ophysiology, however, currently requires regular,
stepped treatment (1,5,6), and recognition of such
treatment has led to the development of a series of
algorithms intended to facilitate timely therapeutic
progression (5,11,12). In particular, one 2007 guide-
line calls for stepping-up treatment within
2–3 months in patients not at goal (12). This new
treatment approach may herald a new level of physi-
cian⁄patient vigilance, and places additional pressure
on researchers and other stakeholders to more con-
cretely deﬁne and address the barriers to effective
glycaemic control.
A growing body of research has indicated that suc-
cessful OAD management is predicated on physician
adherence to treatment algorithms and attention to
patient follow-up (6,7,13). A series of studies has
identiﬁed a link between clinical inertia (in which
health providers delay or fail to start step-up therapy
as recommended) and inadequate glucose control in
well-managed healthcare organisations (6,7). Other
research identiﬁed poor patient adherence as a key
contributor to poor glucose control (9,10). Most
recently, a study by Parchman et al. (8) identiﬁed
the competing demands placed on primary care phy-
sicians during ofﬁce visits as the strongest predictor
of timely medication adjustments in type 2 diabetes;
based on this, the authors posited that clinical inertia
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ity of the problem (8).
There were several limitations to this analysis.
There are a myriad of potential reasons for OAD dis-
continuation (such as adverse events), which could
not be captured using these claims data. Self-moni-
toring of blood glucose or in-ofﬁce glucose tests was
not considered as part of this analysis, but may have
been alternatives to HbA1c testing in the assessment
of patient glucose control. This analysis does not
include the more recently introduced drug regimens
[i.e. glucagon-like peptide-1s (GLP-1s), dipeptidyl
peptidase-4 (DPP-4) inhibitors]. Information on
patient ethnicity was not available in the IHCIS data
set, and there was limited availability of laboratory
values data for a subsample of the initial cohort.
These and other relevant factors that are not cap-
tured in this data set may have had a signiﬁcant
impact on the outcomes studied here; therefore our
ﬁndings should not be considered as proof of any
speciﬁc hypothesis, but rather as conﬁrmation of
associations between certain treatment patterns and
outcomes.
This study conﬁrmed that glucose control in the
US was inadequate between 2001 and 2006, and indi-
cated that this may in part be because of patients
not being transitioned to new OADs in a stepwise
fashion and⁄or not receiving appropriate titration of
current OAD regimens. A possible explanation may
be unwillingness by physicians to either titrate or
add new OADs caused by a perceived lack of efﬁcacy
or tolerability. The current ﬁndings indicated that
only approximately 20–34% of patients received any
index OAD titrations. Current type 2 diabetes man-
agement guidelines focus on adding new OADs to
patient regimens and only brieﬂy address the poten-
tial therapeutic value of up-titrating existing OADs,
in particular MET, to maximum effective dose
(MED) (11). This issue has remained overlooked in
the literature even though MEDs have been identiﬁed
for most OADs (25), and inadequate MED titration
has been documented as a potential contributor to
inadequate glucose control (13,14). Further research
is needed into the clinical decision process for
whether (and how) to intensify OAD treatment regi-
mens, as well as the outcomes associated with each
option.
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